Management of DVT with Subtherapeutic INR

Immediate Management

The American College of Cardiology recommends restarting warfarin therapy and overlapping with low molecular weight heparin (LMWH) until the INR returns to the therapeutic range (2.0-3.0) for at least 24 hours 1, 2
The target INR should be 2.0-3.0 for DVT treatment, as recommended by the American College of Cardiology 1, 3
Low molecular weight heparin (LMWH) should be continued for a minimum of 5 days and until the INR is >2.0 for at least 24 hours, as suggested by the American College of Cardiology and the Journal of the American College of Cardiology 1, 4

Medication interactions affecting warfarin metabolism should be considered, as noted by the American College of Cardiology 5
Poor medication adherence is a factor that may have contributed to the INR drop, as noted by the American College of Cardiology 5

For a first episode of DVT related to a reversible risk factor, the American College of Cardiology recommends 3 months of anticoagulation 3, 6, 7
For a first episode of unprovoked DVT, the American College of Cardiology recommends at least 6 months of anticoagulation 3, 6
For recurrent DVT or unprovoked DVT, the American College of Cardiology suggests considering indefinite anticoagulation with periodic reassessment of risks and benefits 3, 6
For cancer-associated DVT, the American College of Cardiology recommends low molecular weight heparin (LMWH) monotherapy for at least 3-6 months or as long as cancer is active 3, 6

The American College of Cardiology recommends assessing for signs and symptoms of recurrent DVT or bleeding complications at each visit, with a strength of evidence based on clinical guidelines 5
Graduated compression stockings (30-40 mmHg) should be considered for 2 years after DVT diagnosis to reduce the risk of post-thrombotic syndrome, as recommended by the American College of Cardiology 6
Patient education is crucial, including the importance of medication adherence, dietary consistency regarding vitamin K intake, and signs and symptoms of bleeding or recurrent thrombosis, as noted by the American College of Cardiology 5

Failing to bridge with LMWH when INR falls below therapeutic range in a patient with recent DVT is a common pitfall to avoid, as noted by the American College of Cardiology 1, 2
Discontinuing anticoagulation too early, especially in unprovoked DVT, is another common pitfall to avoid, as recommended by the American College of Cardiology 3